Trial Profile
Expanded Access (Compassionate Use) Treatment Protocol Rindopepimut (CDX-110)
Status:
Completed
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 09 May 2019
Price :
$35
*
At a glance
- Drugs Antineoplastics (Primary) ; Bevacizumab (Primary) ; Rindopepimut (Primary) ; Temozolomide (Primary)
- Indications Glioblastoma
- Focus Expanded access; Therapeutic Use
- 16 Oct 2017 Status changed from recruiting to completed.
- 02 Sep 2016 New trial record